Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium–Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Kahkoska, Anna R.
    • Affiliation: Gillings School of Global Public Health, Department of Nutrition
  • Abrahamsen, Trine Julie
    • Other Affiliation: Novo Nordisk A/S
  • Alexander, G. Caleb
    • Other Affiliation: Johns Hopkins Bloomberg School of Public Health
  • Bennett, Tellen D.
    • Other Affiliation: University of Colorado
  • Chute, Christopher G.
    • Other Affiliation: Johns Hopkins University
  • Haendel, Melissa A.
    • Other Affiliation: University of Colorado
  • Klein, Klara R.
    • Affiliation: School of Medicine, Department of Medicine
  • Mehta, Hemalkumar
    • Other Affiliation: Johns Hopkins Bloomberg School of Public Health
  • Miller, Joshua D.
    • Other Affiliation: Stony Brook University
  • Moffitt, Richard A.
    • Other Affiliation: Stony Brook University
  • Stürmer, Til
    • Affiliation: Gillings School of Global Public Health, Department of Epidemiology
  • Kvist, Kajsa
    • Other Affiliation: Novo Nordisk A/S
  • Buse, John B.
    • Affiliation: School of Medicine, Department of Medicine
Abstract
  • OBJECTIVE To determine the respective associations of premorbid glucagon-like peptide-1 receptor agonist (GLP1-RA) and sodium–glucose cotransporter 2 inhibitor (SGLT2i) use, compared with premorbid dipeptidyl peptidase 4 inhibitor (DPP4i) use, with severity of outcomes in the setting of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.RESEARCH DESIGN AND METHODS We analyzed observational data from SARS-CoV-2–positive adults in the National COVID Cohort Collaborative (N3C), a multicenter, longitudinal U.S. cohort (January 2018–February 2021), with a prescription for GLP1-RA, SGLT2i, or DPP4i within 24 months of positive SARS-CoV-2 PCR test. The primary outcome was 60-day mortality, measured from positive SARS-CoV-2 test date. Secondary outcomes were total mortality during the observation period and emergency room visits, hospitalization, and mechanical ventilation within 14 days. Associations were quantified with odds ratios (ORs) estimated with targeted maximum likelihood estimation using a super learner approach, accounting for baseline characteristics. RESULTS The study included 12,446 individuals (53.4% female, 62.5% White, mean ± SD age 58.6 ± 13.1 years). The 60-day mortality was 3.11% (387 of 12,446), with 2.06% (138 of 6,692) for GLP1-RA use, 2.32% (85 of 3,665) for SGLT2i use, and 5.67% (199 of 3,511) for DPP4i use. Both GLP1-RA and SGLT2i use were associated with lower 60-day mortality compared with DPP4i use (OR 0.54 [95% CI 0.37–0.80] and 0.66 [0.50–0.86], respectively). Use of both medications was also associated with decreased total mortality, emergency room visits, and hospitalizations. CONCLUSIONS Among SARS-CoV-2–positive adults, premorbid GLP1-RA and SGLT2i use, compared with DPP4i use, was associated with lower odds of mortality and other adverse outcomes, although DPP4i users were older and generally sicker.
Date of publication
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
Journal title
  • Diabetes Care
Language
  • English
ISSN
  • 0149-5992, 1935-5548

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details dc21-0065.full.pdf 2021-07-07 Public Download